Trudzinski, Franziska C. http://orcid.org/0000-0002-0980-7586
Kellerer, Christina
Jörres, Rudolf A.
Alter, Peter
Lutter, Johanna I.
Trinkmann, Frederik
Herth, Felix J. F.
Frankenberger, Marion
Watz, Henrik
Vogelmeier, Claus F.
Kauczor, Hans-Ulrich
Welte, Tobias
Behr, Jürgen
Bals, Robert
Kahnert, Kathrin
Clinical trials referenced in this document:
Documents that mention this clinical trial
Gender-specific differences in COPD symptoms and their impact for the diagnosis of cardiac comorbidities
https://doi.org/10.1007/s00392-021-01915-x
Prediction of lung emphysema in COPD by spirometry and clinical symptoms: results from COSYCONET
https://doi.org/10.1186/s12931-021-01837-2
Documents that mention this clinical trial
Gender-specific differences in COPD symptoms and their impact for the diagnosis of cardiac comorbidities
https://doi.org/10.1007/s00392-021-01915-x
Prediction of lung emphysema in COPD by spirometry and clinical symptoms: results from COSYCONET
https://doi.org/10.1186/s12931-021-01837-2
Funding for this research was provided by:
bmbf (01 GI 0881)
Universitätsklinikum Heidelberg
Article History
Received: 4 January 2021
Accepted: 22 July 2021
First Online: 31 July 2021
Declarations
:
: Dr. Alter reports grants from German Federal Ministry of Education and Research (BMBF) Competence Network Asthma and COPD (ASCONET), grants from AstraZeneca GmbH, grants and non-financial support from Bayer Schering Pharma AG, grants, personal fees and non-financial support from Boehringer Ingelheim Pharma GmbH & Co. KG, grants and non-financial support from Chiesi GmbH, grants from GlaxoSmithKline, grants from Grifols Deutschland GmbH, grants from MSD Sharp & Dohme GmbH, grants and personal fees from Mundipharma GmbH, grants, personal fees and non-financial support from Novartis Deutschland GmbH, grants from Pfizer Pharma GmbH, grants from Takeda Pharma Vertrieb GmbH & Co. KG, outside the submitted work. Dr. Trinkmann reports personal fees from Actelion, personal fees from Berlin Chemie, personal fees from Boehringer Ingelheim, personal fees from Chiesi, personal fees from Novartis, personal fees from Mundipharma, personal fees from TEVA, personal fees from Bristol-Myers Squibb, personal fees from GlaxoSmithKline, personal fees from Roche, personal fees from AstraZeneca, personal fees from Sanofi-Aventis, outside the submitted work. Prof. Herth received personal money for adboard activities and lecture fees from Pulmonx, BTG, Olympus and Uptake. Prof. Vogelmeier reports grants and personal fees from AstraZeneca, grants and personal fees from Boehringer Ingelheim, grants and personal fees from Chiesi, grants and personal fees from GlaxoSmithKline, grants and personal fees from Grifols, grants and personal fees from Novartis, personal fees from Berlin Chemie/Menarini, personal fees from CSL Behring, grants from German Federal Ministry of Education and Research (BMBF) Competence Network Asthma and COPD (ASCONET), personal fees from Nuvaira, personal fees from MedUpdate, outside the submitted work. Prof. Kauczor reports grants from Siemens, non-financial support from Bayer, during the conduct of the study; grants from Siemens, grants and personal fees from Philips, personal fees from Boehringer Ingelheim, personal fees from Merck Sharp Dohme, personal fees from Astra Zeneca, outside the submitted work. Prof. Welte reports grants from German Ministry of Research and Education, grants from AstraZeneca, GSK, Novartis, Boehringer, during the conduct of the study. Dr. Bals reports grants and personal fees from AstraZeneca, grants and personal fees from Boehringer Ingelheim, personal fees from GlaxoSmithKline, personal fees from Grifols, grants and personal fees from Novartis, personal fees from CSL Behring, grants from German Federal Ministry of Education and Research (BMBF) Competence Network Asthma and COPD (ASCONET), grants from Sander Stiftung, grants from Schwiete Stiftung, grants from Krebshilfe, grants from Mukoviszidose eV, outside the submitted work;.Dr. Trudzinski, Dr. Lutter Ms. Kellerer, Dr. Jörres, Dr. Frankenberger, Dr. Watz Prof. Behr and Dr. Kahnert have nothing to disclose.
: The COSYCONET study complies with the Declaration of Helsinki and Good Clinical Practice Guidelines. All ethical committees of this multi-center study approved COSYCONET, and all patients gave their written informed consent.